November

November 14, 2019

Curing, preventing and reversing diabetes with a commonly available blood pressure drug Hydralazine: Hydralazine-based therapy for TIIDM and obesity-associated metabolic deficits: Hydralazine (trade name: Apresoline, BiDil, and others), a vasodilator used in the treatment of high blood pressure,  cardiac failure and others, increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, decreases TXNIP expression, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM, via down-regulation of its target gene, 14/November/2019, 9.58 am

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that “MC4R-dependent […]
November 8, 2019

Treating advanced cancers resistant to Herceptin and Lapatinib: Probiotic-based Chemotherapy (PCT) targeting cancer stem cells and immune-inhibitory receptors in advanced breast cancers and in other advanced metastatic cancers resistant to Herceptin and Lapatinib: A pharmaceutical mixture encompassing Dacomitinib  (Trade name: Vizimpro, and PF-00299804)  and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as PIAS3, VHL, p53, and TA-p73/p63, INK4a and others, decreases PP2A and Her2 expression, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance mediated by Herceptin and Lapatinib, and stalls advanced breast cancers  progression, and prolongs survival, via up-regulation of its target gene, 8/November/2019, 6.39 pm

Introduction: What they say A study from the Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at University of California, Los Angeles (UCLA), Los Angeles, […]
November 7, 2019

Treating advanced cancers resistant to Paclitaxel/Topotecan/Temozolomide: Probiotic-based Chemotherapy (PCT) targeting cancer stem cells and immune-inhibitory receptors in advanced ovarian cancers and in other advanced metastatic cancers resistant to Paclitaxel/Topotecan/Temozolomide: A pharmaceutical mixture encompassing Veliparib (ABT-888) and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1, CADM1/2,  p53, and TA-p73/p63, INK4a and others, decreases PP2A expression, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance mediated by Paclitaxel/Topotecan/Temozolomide, and stalls advanced ovarian cancers  progression, and prolongs survival, via up-regulation of its target gene, 7/November/2019, 11.59 pm

Introduction: What they say A study from the Department of Gynecologic Oncology and Reproductive Medicine,  University of Texas M.D. Anderson Cancer Center, 1155 Pressler Dr., Houston, TX 77030, […]
November 4, 2019

Curing, preventing, and reversing autoimmune diabetes  (TIDM) with Tellurium Compounds: Ammonium trichloro(dioxoethylene-o,o’)tellurate (AS101), an immunomodulator, increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 4/November/2019, 12.10 pm

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and […]